-
公开(公告)号：US07572772B2
公开(公告)日：2009-08-11
申请号：US11725384
申请日：2007-03-19
IPC分类号： C07K14/705
CPC分类号： C07K16/247 , A61K38/00 , A61K2039/505 , C07K14/70521 , C07K14/7155 , C07K16/00 , C07K16/2818 , C07K16/2827 , C07K2317/34 , C07K2317/73 , C07K2319/00 , C07K2319/30 , Y10S514/885
摘要： The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions.
摘要翻译： 本发明鉴定CTLA4受体作为B7抗原的配体。 提供编码人CTLA4受体基因的完整氨基酸序列。 提供用于表达CTLA4作为免疫球蛋白融合蛋白的方法，用于制备杂合CTLA4融合蛋白，并使用可溶性融合蛋白，其片段和衍生物，包括与B7和CTLA4反应的单克隆抗体调节T细胞相互作用和免疫应答介导 通过这种互动。
-
公开(公告)号：US07070776B1
公开(公告)日：2006-07-04
申请号：US08459766
申请日：1995-06-02
IPC分类号： A61K39/395 , C07K16/28
CPC分类号： G01N33/56972 , A61K38/00 , C07K14/705 , C07K14/70521 , C07K14/70532 , C07K16/2818 , C07K16/2827 , C07K2317/74 , C07K2319/00
摘要： The invention identifies the B7 antigen as a ligand that is reactive with the CD28 receptor on T cells. The invention further provides methods for using antibodies to B7, or fragments thereof, to regulate CD28 positive T cell response and immune responses mediated by T cells.
摘要翻译： 本发明将B7抗原鉴定为与T细胞上的CD28受体反应的配体。 本发明还提供了使用B7抗体或其片段调节CD28阳性T细胞应答和由T细胞介导的免疫应答的方法。
-
13.发明授权Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules 失效使用B7结合分子和IL4结合分子调节免疫应答的方法
公开(公告)号：US5770197A
公开(公告)日：1998-06-23
申请号：US8898
申请日：1993-01-22
IPC分类号： A61K38/00 , A61K38/17 , A61K39/00 , A61K39/395 , A61K45/00 , A61P29/00 , A61P31/12 , A61P31/14 , A61P31/18 , A61P35/00 , A61P37/00 , A61P37/02 , A61P37/06 , A61P37/08 , C07K20060101 , C07K14/00 , C07K14/705 , C07K14/715 , C07K14/725 , C07K16/00 , C07K16/28 , C07K16/42 , C07K19/00 , C12N5/06 , C12N5/10 , C12N15/02 , C12N15/09 , C12N15/12 , C12N15/13 , C12P21/02 , C12P21/08 , C12R1/91 , G01N33/53 , G01N33/564 , G01N33/566 , G01N33/577 , C07K16/46
CPC分类号： C07K16/2827 , C07K14/70521 , C07K14/7155 , C07K16/2818 , A61K38/00 , C07K2317/73 , C07K2319/02 , C07K2319/036 , C07K2319/30 , C07K2319/32 , Y10S424/81 , Y10S530/868
摘要： The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions.
摘要翻译： 本发明鉴定CTLA4受体作为B7抗原的配体。 提供编码人CTLA4受体基因的完整氨基酸序列。 提供用于表达CTLA4作为免疫球蛋白融合蛋白的方法，用于制备杂合CTLA4融合蛋白，并使用可溶性融合蛋白，其片段和衍生物，包括与B7和CTLA4反应的单克隆抗体调节T细胞相互作用和免疫应答介导 通过这种互动。
-
公开(公告)号：US06830937B1
公开(公告)日：2004-12-14
申请号：US09666267
申请日：2000-09-21
IPC分类号： G01N3353
CPC分类号： G01N33/56972 , A61K38/00 , C07K14/705 , C07K14/70521 , C07K14/70532 , C07K16/2818 , C07K16/2827 , C07K2317/74 , C07K2319/00
摘要： The invention provides a method for generating and identifying antibodies directed against a B7 antigen having SEQ ID NO. 8 or a fragment of SEQ ID NO. 8, which antibodies inhibit B cells from binding CD28, comprising immunizing an animal with the B7 antigen so as to produce the antibodies; and screening the antibodies for antibodies that bind B7 and inhibit CD28 binding to B cells.
摘要翻译： 本发明提供了产生和鉴定针对具有SEQ ID NO：1的B7抗原的抗体的方法。 8或SEQ ID NO.1的片段。 8，其抗体抑制B细胞结合CD28，包括用B7抗原免疫动物以产生抗体; 并筛选抗体结合B7并抑制CD28与B细胞结合的抗体。
-
公开(公告)号：US5885796A
公开(公告)日：1999-03-23
申请号：US465078
申请日：1995-06-05
IPC分类号： A61K38/00 , A61P37/02 , C07K14/705 , C07K14/715 , C07K16/00 , C07K16/28 , C12P21/08 , C12P21/02 , C07H21/00 , C07K1/00 , C12N15/00
CPC分类号： C07K14/70521 , C07K14/7155 , C07K16/00 , C07K16/2818 , C07K16/2827 , A61K38/00 , C07K2317/73 , C07K2319/00 , C07K2319/30 , Y10S424/809 , Y10S424/81 , Y10S530/861 , Y10S530/866 , Y10S530/868
摘要： The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions.
-
公开(公告)号：US5580756A
公开(公告)日：1996-12-03
申请号：US219518
申请日：1994-03-29
IPC分类号： A61K38/00 , C07K14/705 , C07K14/725 , C07K16/28 , C12N15/12 , G01N33/569 , C12N15/62 , A61K51/10
CPC分类号： C07K14/70532 , C07K14/705 , C07K14/70521 , C07K16/2803 , C07K16/2818 , C07K16/2827 , G01N33/56972 , A61K38/00 , C07K2317/73 , C07K2319/00 , Y10S514/885 , Y10S530/866 , Y10S530/867 , Y10S530/868
摘要： The invention identifies the B7 antigen as a ligand that is reactive with the CD28 receptor on T cells. Fragments and derivatives of the B7 antigen and CD28 receptor, including fusion proteins having amino acid sequences corresponding to the extracellular domains of B7 or CD28 joined to amino acid sequences encoding portions of human immunoglobulin C.gamma.1, are described. Methods are provided for using B7 antigen, its fragments and derivatives, and the CD28 receptor, its fragments and derivatives, as well as antibodies and other molecules reactive with B7 antigen and/or the CD28 receptor, to regulate CD28 positive T cell responses, and immune responses mediated by T cells. The invention also includes an assay method for detecting ligands reactive with cellular receptors mediating intercellular adhesion.
摘要翻译： 本发明将B7抗原鉴定为与T细胞上的CD28受体反应的配体。 描述了B7抗原和CD28受体的片段和衍生物，包括与编码部分人免疫球蛋白Cγ1的氨基酸序列连接的与B7或CD28的细胞外结构域相对应的氨基酸序列的融合蛋白。 提供了使用B7抗原，其片段和衍生物以及CD28受体，其片段和衍生物以及与B7抗原和/或CD28受体反应的抗体和其它分子调节CD28阳性T细胞应答的方法，以及 由T细胞介导的免疫应答。 本发明还包括检测与介导细胞间粘附的细胞受体反应的配体的测定方法。
-
公开(公告)号：US5434131A
公开(公告)日：1995-07-18
申请号：US67684
申请日：1993-05-26
IPC分类号： A61K38/00 , A61K38/17 , A61K39/00 , A61K39/395 , A61K45/00 , A61P29/00 , A61P31/12 , A61P31/14 , A61P31/18 , A61P35/00 , A61P37/00 , A61P37/02 , A61P37/06 , A61P37/08 , C07K20060101 , C07K14/00 , C07K14/705 , C07K14/715 , C07K14/725 , C07K16/00 , C07K16/28 , C07K16/42 , C07K19/00 , C12N5/06 , C12N5/10 , C12N15/02 , C12N15/09 , C12N15/12 , C12N15/13 , C12P21/02 , C12P21/08 , C12R1/91 , G01N33/53 , G01N33/564 , G01N33/566 , G01N33/577
CPC分类号： C07K14/70521 , C07K14/7155 , C07K16/00 , C07K16/2818 , C07K16/2827 , A61K38/00 , C07K2317/73 , C07K2319/02 , C07K2319/30 , C07K2319/32 , Y10S530/866 , Y10S530/868
摘要： The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions.
摘要翻译： 本发明鉴定CTLA4受体作为B7抗原的配体。 提供编码人CTLA4受体基因的完整氨基酸序列。 提供用于表达CTLA4作为免疫球蛋白融合蛋白的方法，用于制备杂合CTLA4融合蛋白，并使用可溶性融合蛋白，其片段和衍生物，包括与B7和CTLA4反应的单克隆抗体调节T细胞相互作用和免疫应答介导 通过这种互动。
-
公开(公告)号：US07105166B1
公开(公告)日：2006-09-12
申请号：US09609915
申请日：2000-07-03
申请人： Peter S. Linsley , Jeffrey A. Ledbetter , Jurgen Bajorath , Robert J. Peach , William Brady , Philip Wallace , Nitin Damle
发明人： Peter S. Linsley , Jeffrey A. Ledbetter , Jurgen Bajorath , Robert J. Peach , William Brady , Philip Wallace , Nitin Damle
IPC分类号： C07K16/46 , C07K14/705 , C07K14/725
CPC分类号： C07K16/247 , A61K38/00 , A61K2039/505 , C07K14/70521 , C07K14/7155 , C07K16/00 , C07K16/2818 , C07K16/2827 , C07K2317/34 , C07K2317/73 , C07K2319/00 , C07K2319/30 , Y10S514/885
摘要： The present invention provides soluble CTLA4 mutant molecules which bind CD80 and/or CD86 antigen.
摘要翻译： 本发明提供结合CD80和/或CD86抗原的可溶性CTLA4突变分子。
-
公开(公告)号：US6090914A
公开(公告)日：2000-07-18
申请号：US228208
申请日：1994-04-15
IPC分类号： C12N15/00 , A61K38/00 , A61K39/395 , A61P29/00 , A61P31/12 , A61P31/14 , A61P31/18 , A61P35/00 , A61P37/00 , A61P37/02 , A61P37/06 , A61P37/08 , A61P43/00 , C07K14/52 , C07K14/54 , C07K14/705 , C07K14/715 , C07K14/725 , C07K16/00 , C07K16/18 , C07K16/24 , C07K16/28 , C07K16/46 , C07K19/00 , C12N5/00 , C12N5/10 , C12N15/01 , C12N15/09 , C12P21/02 , C12P21/08 , C12R1/91
CPC分类号： C07K14/7155 , C07K14/70503 , C07K14/70521 , A61K38/00 , C07K2317/73 , C07K2319/00 , C07K2319/30
摘要： The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins including CTLA4/CD28 chimeric proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions.
摘要翻译： 本发明鉴定CTLA4受体作为B7抗原的配体。 提供编码人CTLA4受体基因的完整氨基酸序列。 提供用于表达CTLA4作为免疫球蛋白融合蛋白的方法，用于制备包括CTLA4 / CD28嵌合蛋白的杂合CTLA4融合蛋白，并使用可溶性融合蛋白，其片段和衍生物，包括与B7和CTLA4反应的单克隆抗体来调节T 细胞相互作用和由这种相互作用介导的免疫应答。
-
公开(公告)号：US20100330089A1
公开(公告)日：2010-12-30
申请号：US12664166
申请日：2008-06-12
申请人： Nitin K. Damle , Lioudmila Tchistiakova , Kyriaki Dunussi-Joannopoulos , Sandy Alexander Simon , William Brady , Laura Sue Grosmaire , Jeffrey Alan Ledbetter
发明人： Nitin K. Damle , Lioudmila Tchistiakova , Kyriaki Dunussi-Joannopoulos , Sandy Alexander Simon , William Brady , Laura Sue Grosmaire , Jeffrey Alan Ledbetter
IPC分类号： A61K39/395 , C07K16/28 , C07H21/00 , C12N15/63 , C12N5/10 , C12P21/02 , G01N33/566 , A61P37/02 , A61P29/00 , A61P25/00 , A61P35/00
CPC分类号： C07K16/2887 , A61K2039/505 , C07K2317/24 , C07K2317/52 , C07K2317/53 , C07K2317/622 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2319/00
摘要： The present invention provides materials and methods for treatment of diseases involving aberrant B-cell activity, using a CD20-specific binding molecule, in particular, antibodies or antigen binding fragment thereof. The compositions disclosed herein is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies and autoimmune diseases.
摘要翻译： 本发明提供了使用CD20特异性结合分子，特别是抗体或其抗原结合片段治疗涉及异常B细胞活性的疾病的材料和方法。 本文公开的组合物可用于治疗和诊断B细胞病症，例如B细胞恶性肿瘤和自身免疫性疾病。
-
-
-
-
-
-
-
-
-
搜索结果
42 条记录 (耗时 0.038 秒)
